TG Therapeutics (TGTX) Tops Q4 EPS by 7c, provides outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Shipping stocks on fire — but cracks are forming in the rate rally
Cantor Fitzgerald Reiterates Overweight Rating on TG Therapeutics (TGTX)
March 3, 2025 1:07 PM ESTCantor Fitzgerald analyst Prakhar Agrawal reiterated an Overweight rating on TG Therapeutics (NASDAQ: TGTX).
The analyst comments "TGTX stock is up >18% (XBI: -1%) on the back of positive comments on the 4Q call around 1Q trends for Briumvi (anti-CD20 drug in... More
